Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.2720
-0.0010 (-0.37%)
Jun 23, 2026, 2:02 PM EDT - Market open
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $961.00K in the quarter ending March 31, 2026, a decrease of -27.18%. This brings the company's revenue in the last twelve months to $4.71M, down -24.36% year-over-year. In the year 2025, Ensysce Biosciences had annual revenue of $5.07M, down -2.75%.
Revenue (ttm)
$4.71M
Revenue Growth
-24.36%
P/S Ratio
0.85
Revenue / Employee
$470,788
Employees
10
Market Cap
4.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.07M | -143.38K | -2.75% |
| Dec 31, 2024 | 5.21M | 2.98M | 133.58% |
| Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
| Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
| Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
| Dec 31, 2020 | 3.93M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bio Green Med Solution | 1.53M |
| 60 Degrees Pharmaceuticals | 1.31M |
| SciSparc | 856.00K |
| GeoVax Labs | 852.28K |
| Azitra | 7.50K |
ENSC News
- 18 days ago - Ensysce Biosciences files to sell 1.3M shares of common stock for holders - TheFly
- 19 days ago - Ensysce Biosciences Registration statement: Registration filing - Filings
- 5 weeks ago - Ensysce Biosciences Reports First Quarter 2026 Financial Results - Accesswire
- 5 weeks ago - Ensysce Biosciences Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Ensysce Biosciences Earnings release: Q1 2026 - Filings
- 6 weeks ago - Ensysce announces expansion of patent protection for MPAR technology - TheFly
- 6 weeks ago - Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Accesswire
- 6 weeks ago - Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam - Accesswire